Silence Therapeutics Plc - American Depository Share
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Iain Gladstone Ross
- Full Time Employees
- 88
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 72 Hammersmith Road London GL United Kingdom W6 7AP
- IPO Date
- Jan 5, 2010
- Website
- silence-therapeutics.com
- Similar Companies
- Business
- Silence Therapeutics plc (Nasdaq: SLN) develops short interfering RNA (siRNA) therapeutics harnessing the body's RNA interference mechanism to silence specific disease-associated genes, primarily targeting the liver via its proprietary mRNAi GOLD platform; key wholly owned pipeline candidates include zerlasiran (SLN360) for reducing cardiovascular risk in patients with elevated lipoprotein(a), divesiran (SLN124) for hematological disorders such as polycythemia vera, SLN548 for complement-mediated diseases, and earlier-stage programs like SLN312, SLN-140 and SLN-HAN-1/2; the company licenses its platform for partnered programs across cardiovascular, rare hematological, oncology and other areas. Founded in 1994 and headquartered at 12 Hammersmith Grove, London W6 7AP, United Kingdom, Silence Therapeutics maintains operations in the United States (Hoboken, New Jersey) and Germany (Berlin), employing approximately 120 people while generating revenue from research collaborations, royalties and milestones. Recent developments include reporting $43.3 million in full-year 2024 revenues (up from prior year, driven by collaborations with AstraZeneca, Hansoh Pharma and royalties from Alnylam), advancing divesiran to Phase 2 enrollment in polycythemia vera (with Phase 1 follow-up completed and data presentations planned for 2025), preparing zerlasiran for Phase 3 cardiovascular outcomes pending a partner (with FDA positive feedback received and discussions ongoing to extend cash runway into 2027), planning a Phase 1 start for SLN548 in second-half 2025, continuing a Phase 1 study of SLN312 (licensed to AstraZeneca) and regaining global rights to three preclinical targets after Hansoh Pharma opted out of further development.
Company News
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)
Silence Therapeutics jumps 59% on Merck takeover
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Silence Therapeutics (OTCMKTS:SLNCF) Stock Falls 3.7% – Time to Sell?
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial